{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:51:43Z","timestamp":1793469103409,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.radonc.2026.111594","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:28:30Z","timestamp":1778729310000},"page":"111594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-949X","authenticated-orcid":false,"given":"Kristine Wiborg","family":"H\u00f8gsbjerg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6675-7781","authenticated-orcid":false,"given":"Mette Skovhus","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else","family":"Maae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvil","family":"Mjaaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Holck","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-5907","authenticated-orcid":false,"given":"Maja Vestm\u00f8","family":"Maraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8329-7229","authenticated-orcid":false,"given":"Carine","family":"Kirkove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3689-7951","authenticated-orcid":false,"given":"Tamaz","family":"L\u00f6rincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami Aziz-Jowad","family":"Al-Rawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil S","family":"Blix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mechthild","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unn-Miriam","family":"Kasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Wichmann","family":"Matthiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6516-6477","authenticated-orcid":false,"given":"Stine Elleberg","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0814-8179","authenticated-orcid":false,"given":"Jens","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-2096","authenticated-orcid":false,"given":"Birgitte Vrou","family":"Offersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111594_b0005","unstructured":"Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14\u2009324 women in 16 trials. Lancet. 2023;402(10416):1991\u20132003."},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/0284186X.2017.1406139","article-title":"The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial","volume":"57","author":"Berg","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2026.111594_b0015","doi-asserted-by":"crossref","unstructured":"Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51(4):880\u2013914.","DOI":"10.1016\/S0360-3016(01)01749-7"},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2015.12.027","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1","volume":"118","author":"Offersen","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111594_b0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.radonc.2004.02.017","article-title":"Loco-regional conformal radiotherapy of the breast: delineation of the regional lymph node clinical target volumes in treatment position","volume":"71","author":"Dijkema","year":"2004","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.radonc.2015.12.005","article-title":"Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy \u2013 PROCAB guidelines","volume":"118","author":"Verhoeven","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2014.12.012","article-title":"Regional recurrence after adjuvant breast cancer radiotherapy is not due to insufficient target coverage","volume":"114","author":"Nielsen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111594_b0045","unstructured":"NRGoncology. [Available from: https:\/\/www.nrgoncology.org\/RADCOMP-Breast-Atlas."},{"issue":"3","key":"10.1016\/j.radonc.2026.111594_b0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijrobp.2020.04.012","article-title":"Comparison of Nodal Target Volume Definition in Breast Cancer Radiation Therapy According to RTOG Versus ESTRO Atlases: A Practical Review From the TransAtlantic Radiation Oncology Network (TRONE)","volume":"107","author":"Loganadane","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1137","key":"10.1016\/j.radonc.2026.111594_b0055","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220382","article-title":"Mapping of PET\/CT-based regional nodes distribution of recurrent\/advanced breast cancer and comparison with current delineation atlas","volume":"95","author":"Zhang","year":"2022","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.radonc.2016.10.016","article-title":"Three-dimensional analysis of patterns of locoregional recurrence after treatment in breast cancer patients: Validation of the ESTRO consensus guideline on target volume","volume":"122","author":"Chang","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2017.09.031","article-title":"Mapping patterns of locoregional recurrence following contemporary treatment with radiation therapy for breast cancer: A multi-institutional validation study of the ESTRO consensus guideline on clinical target volume","volume":"126","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111594_b0070","article-title":"Hypo- versus standard fractionated loco-regional radiotherapy of patients with high-risk breast cancer in the randomised phase III trial: the DBCG Skagen trial 1","author":"Offersen","year":"2026","journal-title":"Journal of Clinical Oncology In press."},{"issue":"2","key":"10.1016\/j.radonc.2026.111594_b0075","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2017.03.011","article-title":"Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1","volume":"123","author":"Francolini","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111594_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111142","article-title":"Quality assessment of 2705 treatment plans in the randomised Danish Breast Cancer Group Skagen trial 1","volume":"212","author":"Thomsen","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111594_b0085","unstructured":"DBCG. Postoperative Radiotherapy of Breast Cancer, DBCG guidelines: Danish Breast Cancer Group; 2023 [updated 10.03.2023; cited 2023 11.08.2023]. 3.0:[Clinical Practice Guideline]. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/postoperativ-stralebehandling-af-brystkraft\/."},{"key":"10.1016\/j.radonc.2026.111594_b0095","unstructured":"Danish Breast Cancer Cooperative Group Radiotherapy C. Postoperativ radiotherapy. 2014."},{"issue":"1","key":"10.1016\/j.radonc.2026.111594_b0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12885-017-3361-y","article-title":"Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial","volume":"17","author":"de Boniface","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.radonc.2026.111594_b0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.prro.2011.10.001","article-title":"Current clinical coverage of Radiation Therapy Oncology Group-defined target volumes for postmastectomy radiation therapy","volume":"2","author":"Fontanilla","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111594_b0110","article-title":"Hypo- versus standard fractionated loco-regional radiotherapy of patients with high-risk breast cancer in the randomised phase III trial: the DBCG Skagen trial 1","author":"Offersen","year":"2025","journal-title":"Manuscript sudmitted."},{"issue":"9938","key":"10.1016\/j.radonc.2026.111594_b0115","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111594_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111055","article-title":"What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy?","volume":"211","author":"Putora","year":"2025","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2026.111594_b0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","article-title":"Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis","volume":"46","author":"Han","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"29","key":"10.1016\/j.radonc.2026.111594_b0130","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","article-title":"Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures","volume":"26","author":"Fuster","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.radonc.2026.111594_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025556","article-title":"Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.radonc.2026.111594_b0090","unstructured":"DBCG. The DBCG Skagen Trial 1. Moderately hypofractionated loco-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost: DBCG HYPO II, a randomised clinically controlled trial 2015 [Available from: efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.dbcg.dk\/PDF\/SKAGEN_Trial1_protokol_ver_1.0_sept_2015_28.09.2015.pdf."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:45:37Z","timestamp":1783147537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S0167814026004330"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111594","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111594"}}